TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”; TOKYO:4565) is pleased to announce that its wholly-owned subsidiary Heptares Therapeutics (“Heptares”) has been awarded a grant from the National Institute on Drug Abuse (NIDA), one of the US National Institutes of Health. The grant of approximately $5.5 million, with additional funding from Heptares, will support a three-year research project aimed at developing a selective antagonist for the human Orexin-1 receptor for use in treating cocaine addiction and dependence, for which there are currently no approved treatments.
Help employers find you! Check out all the jobs and post your resume.
